CSBTF (Kuros Biosciences) Institutional Ownership: 6.49% (As of Jul. 02, 2026)


CSBTF Kuros Biosciences Ltd CSBTF
71 GF Score
Price $22.72
GF Value $54.99
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Kuros Biosciences Institutional Ownership?

Kuros Biosciences CSBTF 71 Institutional Ownership is 6.49% as of Jul. 02, 2026. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.99 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kuros Biosciences's institutional ownership is 6.49%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kuros Biosciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kuros Biosciences's Float Percentage Of Total Shares Outstanding is 0.00%.

Kuros Biosciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Kuros Biosciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kuros Biosciences Institutional Ownership Chart

Kuros Biosciences Historical Data

The historical data trend for Kuros Biosciences can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 16.18 18.13 18.79 18.58 18.82 18.77 17.79 18.18 18.24 18.11
CSBTF
71GF Score
Kuros Biosciences Ltd CSBTF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kuros Biosciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 6.49% mean?
Kuros Biosciences (CSBTF) has a Institutional Ownership of 6.49% as of Jul. 02, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Kuros Biosciences and its competitors.
Is Kuros Biosciences' Institutional Ownership too high?
Kuros Biosciences' current Institutional Ownership is 6.49%. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Institutional Ownership compare to ABT and SYK?
Kuros Biosciences' Institutional Ownership of 6.49% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Devices & Instruments company?
A good Institutional Ownership depends on the Medical Devices & Instruments industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Kuros Biosciences and its competitors. Kuros Biosciences's current Institutional Ownership is 6.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.99, compared to a current price of $22.72 — trading 58.7% below its estimated fair value. The current Institutional Ownership is 6.49%. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Institutional Ownership is 6.49% as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kuros Biosciences (CSBTF) Overvalued in 2026?

Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued. The current stock price of $22.72 is trading 58.7% below its estimated GF Value™ of $54.99. GuruFocus considers Kuros Biosciences to be Significantly Undervalued.

Key valuation signals for CSBTF:

  • Institutional Ownership: 6.49%
  • GF Value™: $54.99 vs. price of $22.72 (58.7% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kuros Biosciences Business Description

Address Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score

Get the complete analysis for CSBTF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.72
Price
$54.99
GF Value